Announcements Trials

Browse Landscape

Phase

Phase NA 2 Phase 2 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 2013 Carcinoma, Non-Small-Cell Lung 1228 Breast Neoplasms 1215 Leukemia, Myeloid, Acute 969 Neoplasm Metastasis 903 Melanoma 778 Colorectal Neoplasms 752 Multiple Myeloma 725 Lymphoma 725 Ovarian Neoplasms 675 Pancreatic Neoplasms 665 Prostatic Neoplasms 659 Lymphoma, Non-Hodgkin 659 Recurrence 637 Precursor Cell Lymphoblastic Leukemia-Lymphoma 585 Lung Neoplasms 561 Leukemia, Lymphocytic, Chronic, B-Cell 555 Glioblastoma 528 Leukemia 486 Lymphoma, Large B-Cell, Diffuse 441 Lymphoma, Follicular 420 Brain Neoplasms 415 Squamous Cell Carcinoma of Head and Neck 389 Stomach Neoplasms 388 Carcinoma, Renal Cell 385 Myelodysplastic Syndromes 382 Carcinoma, Hepatocellular 368 Advanced Solid Tumors 358 Lymphoma, Mantle-Cell 345 Glioma 344

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Safety Issues × Clear all

NCT05580172 2022-10-17

Phase 1 Study of Oral RH324 in Advanced Non-Small Cell Lung Cancer

ReHeva Biosciences,Inc.

Phase 1 Unknown

Safety Issues

Data powered by HemOnc (CC BY 4.0) Colophon ⚡